Fierce Pharma Fierce Biotech Fierce Healthcare Fierce Life Sciences Events Advertise About Us Biotech Cell & Gene Therapy Clinical Data Venture Capital Deals Research Medtech Devices Diagnostics AI and Machine Learning CRO Special Reports Trending Topics Clinical Development Biologics Fierce 50 Special Report Awards Gala Resources Fierce Events Industry Events Webinars Podcasts Whitepapers Survey Events Subscribe Trending T Biotech Cell & Gene Therapy Clinical Data Venture Capital Deals Research Medtech Devices Diagnostics AI and Machine Learning CRO Special Reports Trending Topics Clinical Development Biologics Fierce 50 Special Report Awards Gala Resources Fierce Events Industry Events Webinars Podcasts Whitepapers Survey Events Subscribe Fierce Pharma Fierce Biotech Fierce Healthcare Fierce Life Sciences Events Advertise About Us Stories Sponsored Allogene abandons leukemia plans for CAR-T in wake of Breyanzi approval Allogene has dropped plans to target one of its allogeneic CAR-Ts at leukemia in the face of competition from the likes of Bristol Myers Squibb. Sponsored How creative chemistry and collaboration synthesized a better drug strategy for Enterin Reshaping the treatment of Parkinson’s, Pfizer CentreOne helped Enterin synthesize a better chemistry for its lead candidate.
Sponsored Allogene abandons leukemia plans for CAR-T in wake of Breyanzi approval Allogene has dropped plans to target one of its allogeneic CAR-Ts at leukemia in the face of competition from the likes of Bristol Myers Squibb.
Sponsored How creative chemistry and collaboration synthesized a better drug strategy for Enterin Reshaping the treatment of Parkinson’s, Pfizer CentreOne helped Enterin synthesize a better chemistry for its lead candidate.
